EP0240344B1

Monoclonal antibodies and their use.

Abstract

This record has no abstract on file.

EP0240344B1, drawing sheet 1 — Sheet 1 of 5

Term

Term ended

Expired 2 April 2007, 19.5 years ago.

5 claims: 2 independent, 3 dependent

1
The use of a monoclonal antibody directed against the CD4 antigen on T-helper lymphocytes for the manufacture of a medicament for the treatment of a mammal to induce tolerance in the said mammal to a primary antigen, the treatment comprising administering to the subject mammal sufficient of the medicament to deplete significantly the population of T-helper lymphocytes in the subject mammal, challenging the subject mammal with the primary antigen and allowing the population of T-helper lymphocytes in the subject mammal to re-establish itself in the presence of the primary antigen so that tolerance to the primary antigen is established.
2
The use according to Claim 1 wherein the primary antigen is an autoantigen or a transplanted antigen.
3
The use according to Claim 1 or 2 wherein the mammal is man.
4
The use according to any of Claims 1 to 3 wherein the treatment also includes administration of another immunosuppressive agent.
5
The use according to Claim 4 wherein the other immunosuppressive agent is an anti-CD8 and/or anti-CD25 monoclonal antibody.

Independent claims5

48 paragraphs, as filed

0001This invention relates to monoclonal antibodies and their use.

0002A major goal in immunology has been to find a means of selectively abolishing an individual's potential to mount an immune response to certain antigens, while preserving responsiveness to others. The facility to induce such specific immunological unresponsiveness in an adult would have major implications for tissue-grafting, the control of allergy and for treatment of autoimmune disease.

0003It has been shown that immunosuppresive regimes, such as irradiation, anti-lymphocyte globulin or thoracic duct drainage, may facilitate tolerance induction. Reference may be had in this context to papers by W.O. Wiegle, Adv. immun., 16, 61-121 (1973) and by G.R. Shellam, Immunology, 17, 267-270 (1969).

0004The preparation of rat monoclonal antibodies, designated YTS 191.1, directed to the L3T4 (CD4) molecule on T-helper cells of mice has been reported by S.P. Cobbold et al, Nature, 312, 548-551 (1984). Moreover D.P. Dialynas et al have described properties of rat monoclonal antibodies, designated GK 1.5, also directed to the L3T4 molecule on T-helper cells, in J. Immun., 131, 2445-2451 (1983), and in Immun. Rev. 47, 29-56 (1983). The L3T4 molecule is the name given to the mouse CD4 molecule. There is a CD4 type molecule on T-helper cells in all mammalian species. Treatment of mice with such monoclonal antibodies leads to rapid depletion of T-helper cells from the blood and lymphoid tissues, with subsequent immunosuppression of a range of immune functions. This latter work has been reported by S.P. Cobbold et al, loc cit, and by D.C. Wofsy et al, J. Immun., 135, 1698-1701 (1985). In this reported work the long term effects of such monoclonal antibodies were studied. D.C. Wofsy et al, loc cit, further reported that L3T4 depleted animals fail to respond on immunisation with protein antigens.

0005Ranges etal., J. Exp. Med., 162, 1105-1110 (1985) reported experiments in which they found that treatment with an anti-L3T4 monoclonal antibody significantly decreased incidence and delayed onset of type II collagen-induced arthritis in mice. This effect appears to result from generalised damage to the immune system (immunosuppression).

0006Waldor etal., Science, 227, 415-417 (1985) disclose that administration of an anti-L3T4 monoclonal antibody prevented development of allergic encephalomyelitis in mice. Again the effect appears to be a general immunosuppressive effect.

0007EP-A-0118794 (Ortho) relates to the production of a hybridoma secreting monoclonal antibodies against OKT4 antigen on normal peripheral helper T-cells. It is proposed, interalia that the monoclonal antibody can be used to treat autoimmune disease caused by excess of helper T-cells. Again the effect is clearly an immunosuppressive effect caused by elimination of helper T-cells.

0008We have now discovered, surprisingly, that certain autoimmune diseases in mammals respond favourably to short term treatment with monoclonal antibodies to the CD4 molecule on helper T-cells.

0009In addition, we have surprisingly, discovered that certain classes of monoclonal antibodies can produce tolerance to a primary antigen. If mammals, such as mice, are exposed to primary antigen challenge during or shortly before a brief period of anti-CD4 therapy, then the treated subject develops tolerance towards that primary antigen after the anti-CD4 therapy has been completed when the challenge with the primary antigen is renewed.

0010The present invention provides the use of a monoclonal antibody directed against the CD4 antigen on T-helper lymphocytes for the manufacture of a medicament for the treatment of a mammal to induce tolerance in the said mammal to a primary antigen, the treatment comprising administering to the subject mammal sufficient of the medicament to deplete significantly the population of T-helper lymphocytes in the subject mammal, challenging the subject mammal with the primary antigen and allowing the population of T-helper lymphocytes in the subject mammal to re-establish itself in the presence of the primary antigen so that tolerance to the primary antigen is established.

0011The period between exposure to the antigen and commencement of the antibody treatment should not be such as to allow the mammal to develop a strong immune response and should preferably not exceed 5 days.

0012As examples of mammals there can be mentioned mice, cats, dogs, horses, cows and man.

0013The amount of anti-CD4 monoclonal antibodies administered should be sufficient for the mammal's helper T-cell population to be significantly depleted.

0014In the treatment of a subject mammal with anti-CD4 monoclonal antibody, treatment is typically carried out so as to reduce the population of helper T-lymphocytes to less than about 20% and preferably to less than about 10% of their normal level. In mice such reduction of the population of helper T-lymphocytes can be achieved, for example, by administration of the antibodies in a series of doses each of the order of about 20mg antibody per kg of body weight. Administration of the antibody can be effected by intravenous or intraperitoneal injection in one or more doses.

0015Sufficient of the antibody is administered in one or more doses to the subject mammal to cause its population of helper T-lymphocytes to be depleted for a limited period. Generally speaking this limited period should be at least 1 day but need not exceed about 14 days. It will normally suffice, so our experiments to date would appear to suggest, to administer the antibody for a period of from 1 to about 7 days, e.g. 3 days. Conveniently the doses of antibody are selected so as to obtain the desired depletion of helper T-lymphocytes by daily injections.

0016Whilst a specific population of T-lymphocytes is depleted in the subject mammal as a result of administration of the anti CD4 antibody, an antigen may be administered to the subject mammal. Such antigen may be administered by injection, by inhalation, by ingestion, by transplantation or by implantation. It may comprise, for example, an immunoglobulin.

0017In our experiments we have shown that mice injected with antigen under the umbrella of an anti-L3T4 (CD4) antibody maintain a record of the encounter manifesting as tolerance, and we have been able to induce tolerance in normal adult mice with an immunogenic form of an antigen.

0018In contrast to other rat IgG2b monoclonal antibodies that deplete lymphocyte populations, anti-L3T4 (CD4), such as YTS 191.1 and GK1.5, both of which are rat IgG2b monoclonal antibodies, do not elicit anti-globulin responses invivo, according to S.P. Cobbold etal., Nature, 312, 548-551 (1984), D.C. Wofsy etal., J. Immun., 135, 1698-1701 (1985) and D. Wofsy etal., J. Exp. Med., 161, 378-391 (1985) as well as S.P. Cobbold etal., Adv. Exp. Med. Bio., 186, 789-795 (1985).

0019The tolerogenic properties of the anti-CD4 antibody have important implications for serotherapy with monoclonal antibodies. By treatment of patients with suitable anti-L3T4 (CD4) monoclonal antibodies at the beginning of such serotherapy it becomes possible to diminish substantially and in some cases to suppress entirely the anti-globulin response normally mounted by the patient's body to the monoclonal antibodies used in such serotherapy.

0020We have also demonstrated that anti-CD4 monoclonal antibodies have an important role to play in correction of the abnormal immune response associated with many forms of autoimmune disease. Although prior reported work has studied the immunosuppressive effects of anti-L3T4 monoclonals, as reported by D. Wofsy etal., J. Exp. Med., 161, 378-391 (1985), by M.K. Waldor etal., Science, 227, 415-417 (1985), by G.E. Ranges etal., J. Exp. Med., 162, 1105-1110 (1985), and by S.W. Brostoff etal., J. Immun., 133, 1938-1942 (1985), and has demonstrated the value of anti-L3T4 (CD4) monoclonals for amelioration of autoimmune diseases in mice and rats, it is surprising that a short burst of anti-L3T4 (CD4) therapy using anti-CD4 monoclonal antibodies can produce long term beneficial effects in treatment of autoimmune diseases. Thus we have shown that so-called "lupus mice", i.e. mice suffering from an autoimmune disease having many of the same symptoms as lupus erythematosus in human beings, have their symptoms ameliorated by injection at the age of four months with daily doses of two anti-L3T4 (CD4) monoclonal antibodies, YTS 191.1 and YTA 3.1 (equivalent to 0.4 mg of monoclonal antibody per dose) for 1 week. There were no deaths in the treated group within 6 months thereafter, although no special precautions were taken (e.g. administration of antibodies or sterilization of their environment), whereas at least 80% of the control animals had died by this time.

0021In another set of experiments we have shown that the immune response of mammals to a primary antigen can be modified by a short course of injections with anti-CD4 monoclonal antibodies begun shortly after the first challenge with the antigen. Thus mice given human γ-globulin as a primary antigen develop tolerance towards it when given subsequently, up to 5 days later, a short course of treatment with monoclonal antibodies to the L3T4 molecule on mice helper T-lymphocytes. Such a short course of treatment may comprise, for example, daily doses for from 3 to 7 days.

0022Allogenic reactions are the major limitation to organ transplants. These are manifested as rejection of the grafted tissue and also in the case of bone marrow transplantation, grant-versus-host disease. By using a combined therapy of CD4 monoclonals and CD8 monoclonals we have been able to produce long term tolerance to skin grafts differing in multiple minor transplantation antigens. Our experiments show that anti-L3T4 (CD4) therapy gave prolonged graft survival, but also demonstrated that optional tolerance induction by anti-L3T4 (CD4) will sometimes require the addition of other immunosuppressive agents.

0023A number of experiments have demonstrated that there are situations where it is insufficient to use monoclonal antibodies against L3T4 (CD4) alone to induce complete immunological tolerance. This is because the L3T4 (CD4) positive T-cells are solely responsible for helping the B-cells produce antibody, but other T-cells which are L3T4 (CD4) negative are separately involved in different types of immune responses. These other T-cells also express specific molecules on their cell surfaces which can be recognised by monoclonal antibodies, in particular, Lyt-2 (CD8) and the IL-2 receptor (CD25). We have shown, in a number of experiments in mouse models, that monoclonal antibodies to Lyt-2 or the IL2 receptor can be used to induce tolerance to protein antigens and even to mismatched tissue grafts when used in combination with the L3T4 (CD4) monoclonal antibodies.

0024The invention is further illustrated in the following Examples:

Example 1

0025This Example demonstrates the return of immunocompetence after YTS 191.1 (anti-L3T4 (a CD4)) treatment in euthymic mice.

0026Male CBA/Ca mice aged 8-12 weeks were depleted of L3T4-positive T-cells by daily injections on days 0 (intravenous (iv.)), 1 and 2 (intraperitoneal (i.p.)) of YTS 191.1 as 0.2ml of ascitic fluid from (DA x LOU) F₁, rats enriched for immunoglobulin by precipitation with 50% saturated ammonium sulphate, and equivalent to 0.4mg of active monoclonal antibody per dose. Controls received saline by the same protocol. Groups of four mice were randomly selected on various days following treatment and immunized with 0.5mg heat-aggregated HGG i.v., purified from group 0 rhesus-positive serum by ammonium sulphate precipitation followed by elution through an ion-exchange chromatographic column (DE52, Whatman) in 0.01 sodium phosphate buffer pH 8.0, dialysed into phosphate-buffered saline (PBS) at 10mg mlR-1F, and then aggregated by heating to 63° for 25 minutes followed by overnight incubation on ice (see W.O. Weigle, Adv. Immun., 16, 61-121 (1973)). Mice were bled from their tail veins 11 days after immunization and the sera stored at -20°C. Serum anti-HGG antibody titres were measured by an enzyme-linked immunosorbent assay (ELISA) as follows. Polyvinyl microtitration trays were coated with purified HGG by incubation of 50µl per well of 20µg ml⁻¹ HGG in PBS for 60 minutes at 37°, washed three times in PBS/0.05% (v/v) Tween 20 (Sigma), and then blocked overnight with 1% (w/v) bovine serum albumin (BSA) in PBS/0.02% (w/v) sodium azide. The trays were then washed and doubling diluations of test sera in 0.1% BSA/PBS were added to each tray at 50µl per well and incubated in 60 minutes at 20°C. A positive control of peroxidase-linked rabbit anti-human immunoglobulin (Dako) was titrated on each tray. The test samples were followed, with intervening washes, by species-specific biotinylated sheep anti-mouse immunoglobulin (Amersham) and then biotinylated streptavidin horseradish peroxidase complex (Amersham) both at 1:1,000 dilution in PBS/0.1% BSA and incubated at 50µl per well for 35 minutes at 20°C. Trays were then washed and developed for 5 min with o-phenylenediamine (100 l per well) and the reaction stopped with 50µl per well of 0.5 M H₂SO₄. Absorbance was read at 490nm, the results plotted graphically and the titres read relative to the positive control. Data are geometric mean ±s.d. of the antibody titres from four mice. The results are summarised in Figure 1. They show that mice challenged with heat-aggregated human γ-globulin (HGG) 2 days after L3T4 depletion generated, as expected, no primary antibody response. However, challenge at day 12 elicited a strong anti-HGG response and at day 42 this response was equivalent to that in untreated controls.

Example 2

0027This Example shows that YTS 191.1 (anti-L3T4 (a CD4)) induces unresponsiveness to its own IgG2b epitopes and to heat-aggregated HGG given concomitantly.

0028Adult CBA/Ca male mice in groups of five were pretreated with three injections of YTS 191.1 as in Example 1 (groups 1, 4, 5), or as controls received an irrelevant IgG2b monoclonal antibody (YTH 65.3.3, anti-human T200 obtained by the method of C. Bindon et al, Transplanation, 40, 538-543 (1985)) (groups 2,6) or saline (groups 3, 7, 8) by the same protocol. Groups 5, 6 and 7 were then injected i.p. on days 2 and 3 with 0.5mg doses of heat-aggregated HGG prepared as in Example 1. Following this pretreatment, mice were maintained on antibiotics (oxytetracyclin 50mgl⁻¹, Terramycin; Pfizer) and were free of any obvious disease. On day 12 all mice were bled and the effectiveness of anti-L3T4 treatment was confirmed by the absence of an antibody response to HGG in group 5 as compared with strong primary responses in group 6 and 7 measured by an ELISA. On days 42 and 52, mice were immunized i.p. with 0.5mg of the heat-aggregated form of YTH 3.2.6 (anti-CD7 IgG2b), of YTH 53.1.4 (anti-human red blood cell, IgG2b), or of HGG. YTH 3.2.6 was prepared by the method described by H. Waldmann et al, Adv. Exp. Med. Biol., 186, 869-875 (1985). YTH 3.2.6 and YTH 53.1.4 were purified from (DA x LOU0F₁ rat ascites by ammonium sulphate precipitation, followed by ion-exchange chromtography in 0.01M sodium phosphate buffer pH 8.0 (DE 52, Whatman) and then heat-aggregated as above. Mice were bled from their tail veins on day 58 and their sera stored at -20°C. The serum titres of antibody to the respective immunizing Ag (YTH 3.2.6, YTH 53.1.4 or HGG) were determined by ELISA as in Example 1. A mixture of mouse monoclonal antibodies against rat immunoglobulin (Norig 7.16.2, Norig 1.1.6, both anti-rat IgG2b obtained as described by N.M. Agel et al, J. Immun. Meth 69, 207-214 (1984)) and mar 18.5 (anti-rat light chain obtained as described by L.L. Lanier et al, Hybridoma, 1, 125-130 (1982)) was used as a reference positive control for measurement of the anti-rat IgG2b antibody responses. Data are geometric means ±s.d. of antibody titres from five mice. The results are plotted in Figures 2(a) and (b). As shown in Figure 2(a), when mice were pre-treated with YTS 191.1, or an irrelevant monoclonal antibody or saline, and then 42 days later were immunized with either of two different heat-aggregated IgG2b monoclonals, having no binding activity for mouse cells (YTH 3.2.6 and YTH 53.1.4), no anti-globulin responses could be detected in anti-L3T4 - treated mice (group 1) compared with controls (groups 2 and 3). Similarly, administration of HGG under the anti-L3T4 umbrella led to later unresponsiveness to re-challenge with this antigen (group 5 in Figures 2(b)). Mice receiving anti-L3T4 but no initial "recording" dose of HGG (group 2), responded as well as controls (groups 6 to 8) to the late HGG challenge.

0029Similar results were obtained with HGG derived from a different donor. Later bleeds did not expose immune responses in tolerant mice.

Example 3

0030This Example demonstrates the specificity of unresponsiveness to rat IgG2b and HGG.

0031Adult male CBA/Ca mice were rendered unresponsive to rat IgG2b by YTS 191.1 (anti-L3T4 antibody) pretreatment as in group 1 in Figure 2(a) or to HGG by pretreatment with YTS 191.1 plus aggregated HGG (anti-L3T4 antibody plus HGG) as in group 5 in Figure 2(b). On days 42 and 52 after induction of unresponsiveness, these mice are age-matched controls were immunized with 0.5mg i.p. of the heat-aggregated form of HGG, CGG or YTH 3.2.6 (rat IgG2b), and then bled on day 58. Chicken γ-globulin was obtained from Miles Laboratories and heat-aggregated as above. Sera were stored at -20°C and antibody titres determined by ELISA. Data are geometric means ±s.d. of antibody titres from five mice. The results were plotted in Figure 3. They show that mice rendered unresponsive to rat Igg2b by administration of anti-L3T4 remained fully responsive to HGG or chicken γ-globulin (CGG). Similarly, mice made unresponsive to HGG given CGG under the anti-L3T4 unbrella responded normally to CGG. Hence the state of unresponsiveness appears to be true tolerance to the administered antigens.

Example 4

0032This example demonstrates the combined use of L3T4 (CD4), Lyt-2 (CD8) and IL-2 (CD25) receptor monoclonal antibodies to generate tolerance to mismatched skin grafts.

0033Male CBA/Ca mice aged 8-12 weeks were given tail skin grafts from mismatched BALB/c mice, together with monoclonal antibody injections three times per week for four weeks. The first five injections were given intravenously, while subsequent injections were intraperitoneally. Figure 4a shows the following groups: control group 1 received no antibody; group 2 received Lyt-2 (CD8) antibodies (TYS 169.4.2 + YTS 156.7.7, 25µg each per injection); group 3 received L3T4 (CD4) antibodies (YTS 191.1.2 + YTA 3.1, 25µg each per injection); group 4 received anti-IL-2 receptor antibody (YCTLD 45.1, 200µg per injection). It can be seen that none of the antibodies alone was sufficient to generate tolerance to the skin grafts, although anti-L3T4 gave a significant prolongation in graft survival. Figure 4b shows that adding the anti-L3T4 and anti-Lyt-2 (group 5) or anti-L3T4 anti-IL-2 receptor antibodies (group 6) together (in the same doses as above) gave a much improved graft survival. Only the combination of all three types of monoclonal antibody allowed any of the mice to maintain the mismatched skin grafts indefinitely and without further treatment (group 7). This demonstrates that optimal tolerance induction by anti-L3T4 (CD4 antibodies) will sometimes require the addition of further immunosuppressive agents, in particular other monoclonal antibodies.

Example 5

0034The following Example shows a typical pharmaceutical preparation for preparing a tolerogenic vaccine using tolerogenic monoclonal antibodies.

0035The tolerogenic vaccine is sterile, pyrogen-free, and free from other abnormal toxicity and will be presented in a lyopholised form in sterile vials.

0036Each vial contains approximately 5mg of sterile freeze-dried tolerogenic monoclonal. The exact amount of monoclonal will be indicated on each vial.

0037The antibody is freeze-dried from 2ml of a solution containing sodium chloride (0.2M), L-histidine (20mM), sorbitol (1%w/v), and human serum albumin (1%w/v). Therefore, each vial contains 23.4mg sodium chloride, 6.2mg L-histidine, and 20mg each of sorbitol and human serum albumin, in addition to the monoclonal.

0038The vials should be stored in a fridge at 2-8°C until reconstitution.

0039They should be used as soon as possible after reconstitution in 2ml of water for injections.

Example 6

0040The following exemplifies a combined pharmaceutical formulation of the present invention comprising a tolerogenic monoclonal and a therapeutic monoclonal antibody.

0041The formulation is sterile, pyrogen free, and free from abnormal toxicity and is presented in a lyopholised form in sterile vials.

0042The tolerogenic antibodies (e.g. anti-CD4) and therapeutic antibody (e.g. anti-CD8) will be dissolved in a solution containing sodium chloride (0.2 M), L-histidine (20 mM), sorbitol (1% w/v), and human serum albumin (1% w/v). The solution will then be subjected to freeze-drying.

Every citation, both ways

Citations
Document	Relation	Office	Cited during
US7037496B2	Cited by	United States of America	Applicant
EP0380542A1	Cited by	European Patent Office (EPO)	Search report
WO9636359A1	Cited by	World Intellectual Property Organization (WIPO)	International search
WO9858966A1	Cited by	World Intellectual Property Organization (WIPO)	International search
EP0380542A4	Cited by	European Patent Office (EPO)	Search report
EP0319333A2	Cited by	European Patent Office (EPO)	Search report
EP0296082A1	Cited by	European Patent Office (EPO)	Search report
EP0704056A1	Cited by	European Patent Office (EPO)	Examiner
WO8911287A1	Cited by	World Intellectual Property Organization (WIPO)	International search
EP0704056B1	Cited by	European Patent Office (EPO)	Examiner
JPH01172345A	Cited by	Japan	Search report
EP0304291A1	Cited by	European Patent Office (EPO)	Search report
EP0296082A1	Cited by	European Patent Office (EPO)	Search report
WO9301834A1	Cited by	World Intellectual Property Organization (WIPO)	International search
EP0304291A1	Cited by	European Patent Office (EPO)	Search report
EP0319333A3	Cited by	European Patent Office (EPO)	Search report
US5152980A	Cited by	United States of America	Search report
WO8809671A1	Cited by	World Intellectual Property Organization (WIPO)	International search
EP0200412A2	Cites	European Patent Office (EPO)	Examiner
EP200412A	Cites	European Patent Office (EPO)	–
EP0018794A	Cites	European Patent Office (EPO)	–
EP0117114A	Cites	European Patent Office (EPO)	–
EP0235805A	Cites	European Patent Office (EPO)	–
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 162, September 1985, The Rockefeller University Press; G.E.RANGES et al., pp. 1105-1110	Non-patent	–	–
NATURE, vol. 312, 06 December 1984; S.P.COBBOLD etal., pp. 548-551	Non-patent	–	–
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 162, July 1985, The Rockefeller University Press; R.L.KIRKMAN et al., pp. 358-362	Non-patent	–	–
THE JOURNAL OF IMMUNOLOGY, vol. 135, no. 3, September 1985, The American Association of Immunologists, US; D.WOFSY et al., pp. 1698-1701	Non-patent	–	–
THE JOURNAL OF IMMUNOLOGY, vol. 126, no. 4, April 1981, The Williams & Wilkins Co., US; T.UCHIYAMA et al., pp. 1393-1397	Non-patent	–	–
THE JOURNAL OF IMMUNOLOGY, vol. 134, no. 2, February 1985, The American Association of Immunologists, US; D.WOFSY et al., pp. 852-856	Non-patent	–	–
SCIENCE, vol. 227, 1985; M.K.WALDOR et al., pp. 415-417	Non-patent	–	–
CHEMICAL ABSTRACTS, vol. 106, no. 3, 19 January 1987, Columbus, OH (US); J.D.SEDGWICK et al., no. 16880e	Non-patent	–	–
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 305, 06 August 1981; A.BENEDICT COSIMI et al., pp. 308-314	Non-patent	–	–
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 164, 1986, The Rockefeller University Press, US; pp. 911-925	Non-patent	–	–
NATURE, vol. 312, 06 December 1984; S.P.COBBOLD etal., pp. 548-551<	Non-patent	–	Examiner
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 305, 06 August 1981; A.BENEDICT COSIMI et al., pp. 308-314<	Non-patent	–	Examiner
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 164, 1986, The Rockefeller University Press, US; pp. 911-925	Non-patent	–	Examiner

5 priority claims, no other members on record

This recordMember, by publication datePriority claim

Priority claims5

Priority claims
Document	Office	Kind	Date
8608068	United Kingdom	A	1986-04-02
8608068	United Kingdom	A	1986-04-02
8608068	United Kingdom	–	1986-04-02
8608068	–	–	–
GB19860008068	–	–	–

37 legal events, as 3 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2007-12-31	Be: patent expiredExpiredBE20	BE20	EP
2007-06-19	Se: european patent has lapsedLapsedEUG	EUG	EP
2007-06-01	Nl: ceased due to reaching the maximum lifetime of a patentCeasedNLV7	NLV7	EP
2007-04-30	Patent ceasedCeasedPL	PL	CH
2007-04-25	Patent expired after termination of 20 yearsExpiredPE20	PE20	GB
2007-04-02	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2007-04-01	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2006-06-14	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-04-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-04-20	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-04-13	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-04-10	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-04-06	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-04-06	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-04-03	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2006-03-29	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2002-01-01	European patent in force as of 2002-01-01IF02	IF02	GB
1995-01-31	Se: european patent in force in swedenEAL	EAL	EP
1994-11-09	No opposition filedOpposition26N	26N	EP
1994-09-22	No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE	PLBE	EP
1994-09-22	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA	STAA	EP
1994-06-21	Lu: last paid annual feeEPTA	EPTA	EP
1994-04-30	It: last paid annual feeITTA	ITTA	EP
1993-12-31	Fr: translation filedET	ET	EP
1993-12-23	Corresponds to:REF	REF	EP
1993-11-18	Designated contracting statesAK	AK	EP
1993-11-18	Miscellaneous (additional remarks)TEILANMELDUNG 92118716.7 EINGEREICHT AM 02/04/87.XX	XX	EP
1993-10-01	(expected) grantORIGINAL CODE: 0009210GRAA	GRAA	EP
1993-08-16	It: translation for a ep patent filedITF	ITF	EP
1993-08-16	It: translation for a ep patent filedITF	ITF	EP
1991-08-28	First examination report despatched17Q	17Q	EP
1990-08-16	Party data changed (applicant data changed or rights of an application transferred)RAP3	RAP3	EP
1989-08-16	Designated contracting statesAK	AK	EP
1989-06-27	Search report despatchedORIGINAL CODE: 0009013PUAL	PUAL	EP
1987-10-07	Request for examination filed17P	17P	EP
1987-10-07	Designated contracting statesAK	AK	EP
1987-08-22	Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI	PUAI	EP

Monoclonal antibodies and their use.

Abstract

Term

Priority claims5

Over the term

Events

Numbers

Titles3

Classification

Designated states1